VNQI - Vanguard Global ex-US Real Est ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
54.67
+0.34 (+0.63%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close54.33
Open54.26
Bid53.20 x 1300
Ask62.00 x 800
Day's Range54.10 - 54.74
52 Week Range52.30 - 65.20
Volume270,127
Avg. Volume526,964
Net Assets6B
NAV52.99
PE Ratio (TTM)N/A
Yield5.53%
YTD Return-10.91%
Beta (3Y Monthly)0.97
Expense Ratio (net)0.14%
Inception Date2010-11-01
Trade prices are not sourced from all markets
  • Morningstar2 months ago

    Model Retirement-Saver Portfolios for Vanguard Investors

    Vanguard is easy to recommend as a destination for investors aiming to simplify their financial lives by investing with a single firm. Morningstar's analyst team gives the firm an A rating for stewardship, owing to its strong corporate culture and ultra-low-cost products. It also fields the largest number of Morningstar Medalist funds of any fund firm.

  • InvestorPlace3 months ago

    7 Real Estate Funds to Buy

    For real estate mutual funds and exchange-traded funds (ETFs), the 2018 story, to this point, is split into two chapters. Amid expectations for rising interest rates, which came to pass, rate-sensitive real estate ETFs and mutual funds slumped in the first several months of 2018.

  • It’s Time to Go Global With Real Estate ETFs
    InvestorPlace6 months ago

    It’s Time to Go Global With Real Estate ETFs

    Savvy dividend investors know that international markets can provide much needed boosts to current income and portfolio yield. Scores of non-US markets, both developed and emerging, sport dividend yields in excess of the S&P 500.7 Stocks to Buy That Lost 10% in April

  • TIPS & Global Real Estate: 2 ETFs to Watch on Outsized Volume
    Zacks9 months ago

    TIPS & Global Real Estate: 2 ETFs to Watch on Outsized Volume

    TDTF and VNQI saw massive trading volume in Friday's trading session.

  • Analysts’ Recommendations for Arrowhead and Its Peers
    Market Realist10 months ago

    Analysts’ Recommendations for Arrowhead and Its Peers

    Incorporated in Delaware, Arrowhead Pharmaceuticals (ARWR) is focused on developing medicines for treating intractable diseases by silencing the genes that cause them. The therapies developed by Arrowhead make use of a broad portfolio of RNA chemistries and efficient modes of delivery to trigger an RNA interference mechanism that induces the rapid and durable knockdown of the target genes. RNA interference or (RNAi) is a mechanism that inhibits the expression of a specific gene.

  • 7 Best Vanguard ETFs For High-Yield Investors
    InvestorPlace10 months ago

    7 Best Vanguard ETFs For High-Yield Investors

    The Federal Reserve hiked interest rates three times last year and more rate increases are expected this year. Still, 10-year Treasuries yield less than 2.7%, underscoring a nearly four-decade downtrend in U.S. borrowing costs. For its part, the S&P 500 yields an anemic 1.8%.